Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
HER-2 negative
Cancer:
Gastric Cancer
Regimen:
(oxaliplatin + capecitabine)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
12/23/2020
Excerpt:
Gastric Cancer: Principles of systemic therapy...Preferred regimens…HER2 overexpression Negative…Fluoropyrimidine (fluorouracil or capecitabine) and oxaliplatin
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login